Cargando…
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer
Prior research suggests a link between circulating levels of follicle-stimulating hormone (FSH) and prostate cancer outcomes. FSH levels may also explain some of the observed differences in cardiovascular events among men treated with gonadotropin-releasing hormone (GnRH) antagonists compared to GnR...
Autores principales: | Kourbanhoussen, Kassim, Joncas, France-Hélène, Wallis, Christopher JD, Hovington, Hélène, Dagenais, François, Fradet, Yves, Guillemette, Chantal, Lacombe, Louis, Toren, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788605/ https://www.ncbi.nlm.nih.gov/pubmed/34259197 http://dx.doi.org/10.4103/aja.aja_58_21 |
Ejemplares similares
-
Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy
por: Desmeules, Patrice, et al.
Publicado: (2015) -
High infiltration of CD209(+) dendritic cells and CD163(+) macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes
por: Molina, Oscar Eduardo, et al.
Publicado: (2023) -
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022) -
Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study
por: Diop, Mame-Kany, et al.
Publicado: (2023) -
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression
por: Lévesque, Eric, et al.
Publicado: (2020)